Answers are grounded in this paper and cite their sources.
Inflammatory breast cancer (IBC) is a rare but aggressive breast cancer that is distinguished from non-IBC by its unique presentation, rapid progression and poor prognosis. Despite these clinical differences, genomic profiling has revealed very few driver mutations that are unique to IBC. Instead, IBC is characterised by enhanced activation of cellular pathways, including NF-kB and JAK/STAT signalling, and a distinct composition of the tumour immune microenvironment (TiME), including increased B cell and macrophage infiltration. How IBC tumour cells and immune cells interact to shape the unique TiME of IBC is largely unknown. We performed a comprehensive analysis of gene expression profiles from IBC and non-IBC patient samples, focusing on the abundance and co-occurrence of B cells with different immune cell subsets. To investigate how IBC cells modulate the TiME, we performed migration assays to determine the chemoattractive capacity of media conditioned by IBC cells (IBC-CM) for peripheral blood mononuclear cells (PBMCs) and B cells, both in the presence and absence of other immune subsets. Secretion of chemokines and cytokines by IBC cells was determined by immunoassays, and their contribution to mediating cell migration was examined using inhibitors and blocking antibodies. Survival analyses were performed to assess the association between immune cell infiltration patterns and patient prognosis. IBC tumours exhibited a higher abundance of B cells compared to non-IBC tumours, a finding that remained consistent across tumours with varying levels of tumour purity. We demonstrated that CXCL1 and CXCL8 produced by established IBC cell lines and primary IBC cells promote B cell migration. In addition, these chemokines also induce activation of the NF-kB and hypoxia pathways in monocytes, leading to increased secretion of IL-6, IL-10 and TNFα, which further amplify B cell recruitment. Analysis of clinical samples confirmed that this intercellular communication network defines a distinct cellular ecotype that is enriched in IBC. Importantly, co-infiltration of CD163+ monocytes/macrophages and CD79α+ B cells was more strongly associated with patient outcomes than either marker alone. IBC is characterised by enhanced inflammatory signalling programmes compared with non-IBC, driven by coordinated crosstalk among tumour cells, myeloid cells and B cells. This tripartite interaction shapes the immune architecture of the IBC TiME and influences patient survival. Therapeutic strategies targeting these interactions could provide novel IBC-specific treatment approaches.
No takes yet. Share an insight, caveat, or question.
Hayward et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: